



Attorney's Docket No.: 00537-165362 / BPC046/US/PCT/US
JL-91
Cheryl A. Caron
3/6/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Anthony Cawthorne et al.

Art Unit : 1653

Examiner : A. Mohamed

Serial No. : 09/423,683

Filed : November 10, 1999

Title : METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND OTHER CONDITIONS

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

FEB 20 2003

RESPONSE TO OFFICE ACTION DATED SEPTEMBER 10, 2002

Prior to examination, please amend the application as follows:

TECH CENTER 1600/2900

In the specification:

Replace the paragraph beginning at page 5, line 3 with the following rewritten paragraph:

C1
[Redacted]
Definitions of "somatostatin type-5 receptor agonist" and "somatostatin type-5 receptor selective agonist" will be given below. A therapeutically effective amount depends upon the condition being treated, the route of administration chosen, and the specific activity of the compound used and ultimately will be decided by the attending physician or veterinarian (e.g., 5 g/day and 5 mg/day). In one embodiment, the somatostatin agonist is administered to the patient until the patient's lipid levels (e.g., glycerol, tracylglycerols, or cholesterol) decrease. In another embodiment, the somatostatin agonist is administered for the lifetime of the patient. [Redacted]

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

February 10, 2003

Signature

Cheryl A. Caron
Typed or Printed Name of Person Signing Certificate